Showing results (211-220 of 602) with videos related to
Sort By:
Pageof 61
Elife|October 16, 2015
Reconstructing the in vivo dynamics of hematopoietic stem cells from telomere length distributionsBenjamin Werner, Fabian Beier, Sebastian Hummel, et al.Cancer Discovery|May 26, 2012
Evolutionary pathways in BRCA1-associated breast tumorsFilipe C Martins, Subhajyoti De, Vanessa Almendro, et al.Journal of Virology|August 13, 2010
Mutations in the stalk region of the measles virus hemagglutinin inhibit syncytium formation but not virus entryMatthew K Ennis, Chunling Hu, Shruthi K Naik, et al.Annals of Hematology|May 18, 2023
Relationship of paroxysmal nocturnal hemoglobinuria (PNH) granulocyte clone size to disease burden and risk of major vascular events in untreated patients: results from the International PNH RegistryDavid Dingli, Jaroslaw P Maciejewski, Loree Larratt, et al.Health and Quality of Life Outcomes|August 9, 2024
Patient-reported outcomes and daily activity assessed with a digital wearable device in patients with paroxysmal nocturnal hemoglobinuria treated with ravulizumab: REVEAL, a prospective, observational studyElizabeth A Griffiths, Jae S Min, Wei-Nchih Lee, et al.Genes & Development|April 11, 2018
Increased HOXA5 expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastomaPatrick J Cimino, Youngmi Kim, Hua-Jun Wu, et al.Cancer Discovery|April 2, 2026
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapiesMarie-Anne Goyette, Christopher Graser, Marco Seehawer, et al.AJR. American Journal of Roentgenology|July 24, 2010
Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancerAlan R Penheiter, Troy R Wegman, Kelly L Classic, et al.Plos One|April 27, 2019
Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategiesKimiyo N Yamamoto, Akira Nakamura, Lin L Liu, et al.Transfusion|February 17, 2025
Increasing use of CAR-T therapy occurs in conjunction with decreasing stem cell transplants with stable resource usage over a 6-year period: Resource utilization implicationsAswath P Chandrasekar, Margret A DiGuardo, Jeffrey L Winters, et al.Pageof 61